Growth differentiation factor 15 in different stages of heart failure: potential screening implications.
Identification of individuals in the early stage of heart failure (HF) may allow earlier initiation of disease-modifying treatment. We evaluated concentrations of the growth differentiation factor (GDF)-15 at different stages and its potential screening value in 208 subjects. Plasma GDF-15 was measured by using an enzyme-linked immunosorbent assay. GDF-15 was positively correlated with the stages of HF (r=0.804, p<0.001). In distinguishing patients with stage B HF, the area under the curve was 0.873 (p<0.001). These findings indicate that GDF-15 concentration was elevated with the progressing stages of HF and might have potential screening implications for stage B HF.
Wang
Fangfang
F
Peking University Third Hospital, Peking University Health Science Center and Key Laboratory of Molecular Ministry of Education, Cardiovascular Science, Beijing, China.
Guo
Yanhong
Y
Yu
Haiyi
H
Zheng
Lingbing
L
Mi
Lin
L
Gao
Wei
W
D000368:Aged; D015415:Biomarkers / Q000097:blood*; D004452:Echocardiography; D005260:Female; D055436:Growth Differentiation Factor 15 / Q000097:blood*; D006333:Heart Failure / Q000097:blood* / Q000175:diagnosis / Q000000981:diagnostic imaging; D006801:Humans; D008297:Male; D008403:Mass Screening / Q000379:methods*; D008875:Middle Aged; D020097:Natriuretic Peptide, Brain / Q000097:blood; D010446:Peptide Fragments / Q000097:blood; D012372:ROC Curve
D015415:Biomarkers; D055436:Growth Differentiation Factor 15; D010446:Peptide Fragments; C109794:pro-brain natriuretic peptide (1-76); D020097:Natriuretic Peptide, Brain